You can sit there picturing a plate of pasta. You can smell it, want it, narrate your desire to anyone nearby. The drug doesn’t care. Because GLP-1 receptor agonists aren’t working on your thoughts – they’re working upstream of them.
This is the part most explanations skip. Appetite suppression on semaglutide or tirzepatide isn’t about liking food less, or deciding to eat less, or building discipline. It’s about a shift in the biological machinery that generates hunger before hunger ever reaches the level of awareness. The mechanism lives in the hypothalamus. Your prefrontal cortex – the part doing the picturing and the narrating – is downstream, and largely irrelevant to what the drug is doing.
Understanding where GLP-1s act, and where they don’t, changes how you interpret the experience of being on them.
The Two Neurons That Decide Whether You Eat
Deep inside the arcuate nucleus of the hypothalamus sit two populations of neurons that function like opposing switches for hunger. They don’t receive your opinions about food. They receive metabolic signals – leptin, ghrelin, insulin, peptide YY – and they fire accordingly.
The first population is POMC neurons (pro-opiomelanocortin). When active, they release alpha-MSH, which travels to the paraventricular nucleus and signals: satiety, reduce intake, increase energy expenditure. The second population is AgRP neurons (agouti-related peptide). When active, they do the opposite: they block POMC signaling, suppress the satiety response, and generate a powerful drive to eat. They also produce NPY (neuropeptide Y), which amplifies hunger further.
These two populations are perpetually in competition. The outcome of that competition
- not your conscious deliberation – determines whether you feel hungry.
What matters: both operate below the level of voluntary control. You cannot decide to silence AgRP neurons. You cannot will POMC neurons to fire harder. The competition plays out in the arcuate nucleus, and your experience of hunger or fullness is the downstream readout of it.
Where GLP-1 Receptors Actually Land
GLP-1 receptors are not evenly distributed across the brain. They cluster in specific regions – and those regions are not where deliberate thought happens.
The highest densities of GLP-1 receptor expression in the central nervous system are found in the arcuate nucleus of the hypothalamus (where POMC and AgRP neurons live), the nucleus tractus solitarius in the brainstem (a key hub for gut-brain vagal signaling), and the area postrema (the brainstem’s chemosensor for circulating hormones and drugs). Research published in Endocrinology (Trapp & Hisadome, 2011) mapped GLP-1 receptor expression across rodent and human brain tissue and confirmed this subcortical and brainstem-dominant distribution.
The prefrontal cortex – where you deliberate, imagine, plan, and narrate – has comparatively sparse GLP-1 receptor expression. This is not incidental. It reflects what GLP-1 is actually for in the body: it’s an incretin hormone released from gut L-cells after eating, designed to signal satiety to the brainstem and hypothalamus. Its biological job is to talk to hunger systems, not thought systems.
Receptor agonist drugs like semaglutide and tirzepatide exploit that same pathway. They bind where the natural hormone binds. The architecture was never wired to your conscious experience.
Why ‘Thinking About Food’ Changes Nothing
Consider the distinction between craving as image and craving as drive.
When you see a pizza ad and feel a flicker of interest, that’s a cortical event – visual processing, memory association, anticipatory reward signaling from the prefrontal cortex and orbitofrontal cortex. It’s a thought-level experience. It can feel compelling. But it isn’t the same system that generates the biological drive that makes you open the fridge at midnight after a poor night of sleep, shaky and unable to focus until you eat.
That second state – genuine homeostatic hunger – originates in the arcuate nucleus. It’s driven by AgRP neuron activity, and it operates more like a smoke alarm than a preference. You don’t choose to feel it; it simply escalates until addressed.
GLP-1 drugs intercept the alarm. They don’t touch the cortical layer where food images live. This is why many users on GLP-1 therapy report a specific phenomenology: they can still appreciate the sight of food, still find it appealing on some intellectual level, but the urgency is absent. The alarm isn’t going off. Food remains interesting. It’s just no longer demanding.
AgRP Silencing: The Mechanism That Sticks
The most direct explanation for why GLP-1s work on hunger regardless of food thoughts: semaglutide and tirzepatide, through GLP-1 receptor activation, suppress AgRP neuron firing in the arcuate nucleus.
A 2021 study in Nature Metabolism (Brierley et al.) examined how GLP-1 receptor agonism affects hypothalamic neuron populations. GLP-1 receptor activation increased POMC neuron activity and concurrently reduced AgRP neuron firing. This dual effect – activating the ‘stop eating’ signal and suppressing the ‘eat now’ signal – operates at the level of synaptic transmission, not conscious processing.
The silencing of AgRP neurons has consequences that ripple through the hunger system. AgRP neurons don’t just drive immediate intake – they suppress competing satiety signals for hours. When AgRP activity is high, even elevated leptin has reduced effectiveness. When AgRP is suppressed by GLP-1 receptor activation, that blockade lifts, and satiety signals from leptin, PYY, and CCK are able to register more clearly.
This is the mechanism behind what users describe when they say food noise goes quiet. It isn’t a psychological shift. It isn’t mindfulness. The AgRP-driven urgency that normally competes with and overrides satiety signals is simply less present. What remains is a clearer signal environment where the body’s own fullness cues can actually land.
What This Means for How You Think About Cravings
The common framework for cravings puts willpower at the center: you want something, you decide whether to act on it. Cravings, in this framing, are a test of self-regulation.
GLP-1 neuroscience suggests a different model. Cravings aren’t a single event – they’re a layered system. The cortical layer (imaging, anticipating, remembering) is real. The homeostatic layer (AgRP-driven urgency, mounting biological drive) is different, and it’s the homeostatic layer that usually wins long-term contests against the prefrontal cortex.
GLP-1 receptor agonists intervene at the homeostatic layer. They don’t prevent cortical food engagement – you can still want food in the intellectual sense. What they reduce is the mounting biological pressure that eventually overwhelms deliberate choice. The competition between POMC and AgRP neurons shifts. The alarm volume drops.
For people who have spent years attributing failed diets to insufficient willpower, this reframe carries weight. The mechanism that was working against them wasn’t a character flaw. It was AgRP neuron activity in the arcuate nucleus, a system they had no direct access to and no tool to modulate – until now.
The experience of reduced food noise on GLP-1 therapy isn’t a placebo effect and it isn’t psychological distance from food. It’s a measurable shift in hypothalamic neuron firing patterns – the same patterns that were generating the biological demand for intake regardless of what you consciously wanted to eat or not eat. The drug works where hunger lives, not where thoughts about food live. That distinction is worth holding.
If this kind of mechanistic breakdown is useful to you, Metabolic Field Notes publishes one piece like this each week – no protocols, no plans, just the science of how the body actually works. You can join the field notes below.
Join the Field Notes
Metabolic Field Notes tracks the evidence as it develops, without protocol-pushing and without hype. If evidence-aware, translational science is useful to you, join the Field Notes.
Medical Disclaimer: The content on this blog is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
